medical glp 1 New GLP-1 Guidelines for Type 2 Diabetes in 2025 1 journey with Side Effect Relief GLP-1

What Now

It first received Emergency Use Authorization (EUA) from the FDA in December 2020

Medicare prescription plans do not cover weight-loss medications, although they often cover Wegovy and Zepbound for other FDA-approved purposes, such as treating obstructive sleep apnea (Zepbound) or lowering the risk of major cardiovascular events (Wegovy)

The trend is called microdosing GLP-1s, and its becoming more common

doi: 10.1016/j.redox.2017.04.019

As AUD is a heterogeneous disorder with a multifaceted pathophysiology, the possibility that combinations of GLP-1 and other gutbrain axis peptides synergistically reduce alcohol drinking should be explored in future studies